Literature DB >> 27262250

PURLs: Resistant hypertension? Time to consider this fourth-line drug.

Alexander Kaysin1, Anne Mounsey1.   

Abstract

For most adults with resistant hypertension, spironolactone is superior to doxazosin and bisoprolol as an adjunct to triple therapy.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27262250      PMCID： PMC4832049     

Source DB:  PubMed          Journal:  J Fam Pract        ISSN： 0094-3509            Impact factor:   0.493


  8 in total

1.  Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study.

Authors:  Ján Rosa; Petr Widimský; Petr Toušek; Ondřej Petrák; Karol Čurila; Petr Waldauf; František Bednář; Tomáš Zelinka; Robert Holaj; Branislav Štrauch; Zuzana Šomlóová; Miloš Táborský; Jan Václavík; Eva Kociánová; Marian Branny; Igor Nykl; Otakar Jiravský; Jiří Widimský
Journal:  Hypertension       Date:  2014-11-24       Impact factor: 10.190

2.  Spironolactone use and renal toxicity: population based longitudinal analysis.

Authors:  Li Wei; Allan D Struthers; Tom Fahey; Alexander D Watson; Thomas M Macdonald
Journal:  BMJ       Date:  2010-05-18

3.  2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).

Authors:  Paul A James; Suzanne Oparil; Barry L Carter; William C Cushman; Cheryl Dennison-Himmelfarb; Joel Handler; Daniel T Lackland; Michael L LeFevre; Thomas D MacKenzie; Olugbenga Ogedegbe; Sidney C Smith; Laura P Svetkey; Sandra J Taler; Raymond R Townsend; Jackson T Wright; Andrew S Narva; Eduardo Ortiz
Journal:  JAMA       Date:  2014-02-05       Impact factor: 56.272

4.  The Effects of Aldosterone Antagonists in Patients With Resistant Hypertension: A Meta-Analysis of Randomized and Nonrandomized Studies.

Authors:  Khagendra Dahal; Sumit Kunwar; Jharendra Rijal; Fahad Alqatahni; Raju Panta; Noshi Ishak; Roy Patterson Russell
Journal:  Am J Hypertens       Date:  2015-03-23       Impact factor: 2.689

5.  Efficacy of low-dose spironolactone in subjects with resistant hypertension.

Authors:  Mari Konishi Nishizaka; Mohammad Amin Zaman; David A Calhoun
Journal:  Am J Hypertens       Date:  2003-11       Impact factor: 2.689

6.  Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial.

Authors:  Christina S Oxlund; Jan E Henriksen; Lise Tarnow; Karoline Schousboe; Jeppe Gram; Ib A Jacobsen
Journal:  J Hypertens       Date:  2013-10       Impact factor: 4.844

7.  Effect of spironolactone in resistant arterial hypertension: a randomized, double-blind, placebo-controlled trial (ASPIRANT-EXT).

Authors:  Jan Václavík; Richard Sedlák; Jiří Jarkovský; Eva Kociánová; Miloš Táborský
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

8.  Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.

Authors:  Bryan Williams; Thomas M MacDonald; Steve Morant; David J Webb; Peter Sever; Gordon McInnes; Ian Ford; J Kennedy Cruickshank; Mark J Caulfield; Jackie Salsbury; Isla Mackenzie; Sandosh Padmanabhan; Morris J Brown
Journal:  Lancet       Date:  2015-09-20       Impact factor: 79.321
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.